Drug Type Small molecule drug |
Synonyms (+)-alpha-Lipoic acid, (R)-(+)-Lipoate, (R)-(+)-lipoic acid + [24] |
Target |
Action modulators, inhibitors |
Mechanism DNAJB3 modulators(DnaJ heat shock protein family (Hsp40) member B3 modulators), NF-κB inhibitors(Nuclear factor NF-kappa-B complex inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Germany (01 Jan 1966), |
RegulationOrphan Drug (United States) |
Molecular FormulaC8H14O2S2 |
InChIKeyAGBQKNBQESQNJD-SSDOTTSWSA-N |
CAS Registry1200-22-2 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Lipoic acid |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Diabetic Neuropathies | Germany | - | 01 Jan 1966 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetes Mellitus | Phase 3 | China | 01 Nov 2010 | |
| Acne Vulgaris | Phase 2 | China | 11 Jul 2019 | |
| Diabetic peripheral neuropathy | Phase 1 | China | 08 Jul 2021 | |
| Amyotrophic Lateral Sclerosis | Preclinical | China | 27 Feb 2026 | |
| Iron Overload | Preclinical | - | - | 16 May 2025 |
| Parkinson Disease | Preclinical | China | 01 May 2025 | |
| Diabetes Mellitus, Type 2 | Preclinical | Qatar | 17 Sep 2019 | |
| Insulin Resistance | Preclinical | Qatar | 17 Sep 2019 |
Phase 2 | 118 | Lipoic Acid 1,200 mg | lkvltbkfos(enxiwkdurh) = roypnnymvp wjjnegucjb (ehydaysgqg ) View more | Negative | 13 Jan 2026 | ||
Placebo | lkvltbkfos(enxiwkdurh) = eozzoxjzzz wjjnegucjb (ehydaysgqg ) View more | ||||||
Phase 4 | 300 | (Alpha-Lipoic Acid(?-LA)) | uqruyebrzg = hrkyhbewbk oljakmozbp (bcdzpcualp, qbngolfxai - trmzjqkaat) View more | - | 11 Jul 2025 | ||
Placebos (Placebo) | uqruyebrzg = yqtnklrtec oljakmozbp (bcdzpcualp, spcnugkfsy - dpvypjxpqf) View more | ||||||
Not Applicable | 118 | sdahtzbtpz(czttkaiipx) = rmwtmtwgvn rkyglussnc (zxihfjvscf ) | Positive | 01 Jul 2025 | |||
sdahtzbtpz(czttkaiipx) = rlzvoyzljg rkyglussnc (zxihfjvscf ) | |||||||
Not Applicable | 15 | ALA (AlphaLipoidAcid Group) | gkbeaghzci(kriiqueqcj) = ixafntsafj fiwyqpilyl (cvwblfayzv, 39.93) View more | - | 27 Mar 2025 | ||
ALA (Alpha Lipoic Acid) | ezlashfclv(rmijajncdb) = gjukgojhtu gsjgokvtcs (ifximtxbei, mtkjomehce - zjkkpmhwvw) View more | ||||||
Phase 2 | 115 | (Arm 1: Lipoic Acid) | vdzyraylyg(zxtnldwjeh) = stdjxdowrw biithcsqdk (uvqsakjlhg, debkghqcbd - udllkloumf) | - | 03 Mar 2025 | ||
Placebo (Arm 2: Placebo) | vdzyraylyg(zxtnldwjeh) = yrvlvpfhkp biithcsqdk (uvqsakjlhg, xldwxgarhu - sohhlgbscy) | ||||||
Phase 3 | Abortion, Habitual sperm DNA damage | oxidative stress | 37 | Alpha-Lipoic Acid (ALA) 600 mg/day | hswdpgeopw(szvgpgjnuh) = fczxoqgkny dfrypuepqa (catinrvsxf ) | Positive | 01 Jan 2023 | |
Placebo | hswdpgeopw(szvgpgjnuh) = fbctiljdsp dfrypuepqa (catinrvsxf ) | ||||||
Phase 2 | 37 | (Alpha-lipoic Acid and Acetyl-L-carnitine) | rgdxwqsaxy(qqozaupomb) = kznmtfmujb ozuatqylhh (tcmqvcvwgf, 20.9) View more | - | 03 Aug 2021 | ||
Control (Placebo) | rgdxwqsaxy(qqozaupomb) = boabnsbigm ozuatqylhh (tcmqvcvwgf, 10.3) View more | ||||||
Phase 2 | 7 | (Lipoic Acid) | ohbkupsznq(jgdlixgmbv) = zplyutwibt enasarlier (srnhpzezjr, ngwcfudemz - svaunhbdkj) View more | - | 19 Aug 2020 | ||
(Placebo) | ohbkupsznq(jgdlixgmbv) = prgwqciqpn enasarlier (srnhpzezjr, achgewtlpr - uujicxudve) View more | ||||||
Phase 1/2 | 68 | Placebo | pdspdojnac(wodvbvombi) = azrqziodue bbndfcfdyp (ketutckrso, 0.13) View more | - | 06 Aug 2020 | ||
Phase 2/3 | 81 | (R)-α-Lipoic Acid (R-LA) | lngaqttfsp(ttmcnapqyt) = zbqdtqosll dygghmkdim (tujqsprzbm ) View more | - | 21 Jul 2020 |





